Cost Reimbursable, Cost Sharing Milestone Payment Method Sample Clauses

The Cost Reimbursable, Cost Sharing Milestone Payment Method clause defines how payments are made based on the reimbursement of allowable costs, with both parties sharing certain expenses, and payments tied to the achievement of specific project milestones. Under this arrangement, the contractor is reimbursed for a portion of actual costs incurred, while the client and contractor agree to share costs according to a predetermined ratio, and payments are released as each milestone is completed. This clause ensures that financial risk is distributed between the parties and that payments are linked to measurable progress, promoting accountability and incentivizing timely completion of project phases.
POPULAR SAMPLE Copied 1 times
Cost Reimbursable, Cost Sharing Milestone Payment Method. (with not to exceed ceiling): Payment is contingent upon satisfactory progress toward completion of milestones as delineated in Project Agreement and acceptable cost share. Payment shall be made based on actual costs incurred in completing milestones up to the maximum amount allowable under the applicable Project Agreement, provided the designated AOR has verified compliance with the Statement of Work and accomplishment of the stated effort. Per (ii) below, either a Status Report identifying any associated technical tasks and the progress toward completion of each milestone, a Deliverable Report, or a Milestone Report is required concurrent with the invoice. An acceptable invoice for reimbursable payment is one that (on the invoice or on the attached Status, Deliverable, or Milestone Report in accordance with each Project Agreement): (i) contains the date of invoice and the Base Agreement number and Project Agreement number; (ii) identifies any associated technical milestones and the progress toward completion of each milestone; (iii) includes a report of the cost share expended towards the accomplishment of the SOW tasks and/or milestones. This cost share report may be attached to the invoice if contractor practices make inclusion of such information on the invoice itself impractical. If the cost share report is separate from the invoice, it must be signed by an authorized representative. This cost share report must contain a breakout of the cost share by cost element similar to the level of detail required on the invoice and any in-kind contributions. The preferred method of reporting cost share is to provide an invoice for actual cost incurred with a value for the cost shared amount and the value to be reimbursed by the Government through the CMF; (iv) includes a description of supplies and services, labor costs, subcontractor costs, material costs, travel costs, other direct costs, and extended totals; (v) indicates the current period and cumulative man-hours and costs incurred through the period indicated on the invoice; and
View SourceView Similar (11)
Cost Reimbursable, Cost Sharing Milestone Payment Method. (with not to exceed ceiling): Payment is contingent upon satisfactory progress toward completion of milestones as delineated in Prototype Award and acceptable cost share. Payment shall be made based on actual costs incurred in completing milestones up to the maximum amount allowable under the applicable Prototype Award, provided the designated AOR has verified compliance with the Statement of Work and accomplishment of the stated effort. Per (ii) below, either a Status Report identifying any associated technical tasks and the progress toward completion of each milestone, a Deliverable Report, or a Milestone Report is required concurrent with the invoice. An acceptable invoice for reimbursable payment is one that (on the invoice or on the attached Status, Deliverable, or Milestone Report in accordance with each Prototype Award):
View SourceView Similar (2)
Cost Reimbursable, Cost Sharing Milestone Payment Method. (with not to exceed ceiling): Payment is contingent upon satisfactory progress toward completion of milestones as delineated in Project Agreement and acceptable cost share, and subject to Article 25, Allowable Costs. Payment shall be made based on actual costs incurred in completing milestones up to the maximum amount allowable under the applicable Project Agreement, provided the designated AOR has verified compliance with the Statement of Work and accomplishment of the stated effort. Per (iii) below, either a status report identifying any associated technical tasks and the progress toward completion of each milestone, a deliverable report, or a milestone report is required concurrent with the invoice. An acceptable invoice for reimbursable payment is one that (on the invoice or on the attached status, deliverable, or milestone report in accordance with each Project Agreement): i. Is addressed to: Advanced Technology International 315 Sigma Dr.‌ ▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ii. contains the date of invoice, invoice number, and the Base Agreement and Project Agreement number;
View Source
Cost Reimbursable, Cost Sharing Milestone Payment Method. (with not to exceed ceiling): Payment is contingent upon satisfactory progress toward completion of milestones as delineated in OTIA and acceptable cost share. Payment shall be made based on actual costs incurred in completing milestones up to the maximum amount allowable under the applicable OTIA, provided the designated AOR has verified compliance with the Statement of Work and accomplishment of the stated effort. Per (3) below, either a Status Report identifying any associated technical tasks and the progress toward completion of each milestone, a Deliverable Report, or a Milestone Report is required concurrent with the invoice. An acceptable invoice for reimbursable payment is one that (on the invoice or on the attached Status, Deliverable, or Milestone Report in accordance with each OTIA): a. Is addressed to the CMF and contains the CMF’s address; Advanced Technology International ▇▇▇ ▇▇▇▇▇ ▇▇. Summerville, SC 29486 b. contains the date of invoice and agreement number (20XX-XXX OTIA X);
View Source
Cost Reimbursable, Cost Sharing Milestone Payment Method. (with not to exceed ceiling) for Consortium Members subject to full Cost Accounting Standards on other agreements or contracts: Payment is contingent upon satisfactory progress toward completion of milestones as delineated in each Project Agreement and acceptable cost share, and subject to Article 25, Allowable Costs, paragraph 3. Invoices submitted that include charges for travel, subsistence, and lodging shall be supported by a copy of the employee's travel expense report, or itemized report, with copies of all receipts for expenses in excess of $75 to be kept on file at the Consortium Members’ facility. These supporting documents will not be submitted to CM but shall be maintained at the Consortium Members’ facility, and should the circumstances dictate, copies of the substantiating document(s) shall be provided to the appropriate Government audit agency. All travel charges for meals, incidental expenses (M&IE) and lodging shall be at the Government Per Diem Rates found at: ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/travel/plan-book/per-diem-rates. Payment shall be made based on actual costs incurred in completing milestones up to the maximum amount allowable under the applicable Project Agreement, provided the designated AOR has verified compliance with the Statement of Work and accomplishment of the stated effort. Per (iii) below, either a status report identifying any associated technical tasks and the progress toward completion of each milestone, a deliverable report, or a milestone report is required concurrent with the invoice. An acceptable invoice for reimbursable payment is one that (on the invoice or on the attached status, deliverable, or milestone report in accordance with each Project Agreement): i. Is addressed to the CM and contains the CM’s address: Advanced Technology International Summerville, SC 29486 ii. contains the date of invoice, invoice number, and the Base Agreement and Project Agreement number (20XX-XXX Project Agreement X);
View Source

Related to Cost Reimbursable, Cost Sharing Milestone Payment Method

  • Sales Milestone Payments Artiva shall make the following one-time, non-refundable and non-creditable sales milestone payments to GCLC when the aggregate annual Net Sales of Products in the Territory first reach the thresholds specified below. Artiva shall notify GCLC promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Artiva within [***] days after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any given calendar year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such calendar year. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.

  • Milestone Fees Licensee will pay Milestone Fees indicated in Section 3.1(b) of the Patent & Technology License Agreement by the Quarterly Payment Deadline for the Contract Quarter in which the milestone events set forth in Section 3.1(b) of the Patent & Technology License Agreement are achieved.

  • Milestone Event Milestone Payment [***] [***]

  • Milestone Payment The first time Net Sales in the Territory in a Royalty Period exceed [***] [***]